The most common adverse drug reaction associated with the use of<unk>  (>10% of people) is reversible ovarian enlargement. Less common effects (1–10% of people) include visual symptoms (blurred vision, double vision, floaters, eye sensitivity to light, scotomata), headaches, vasomotor flushes (or hot flashes), light sensitivity and pupil constriction, abnormal uterine bleeding and/or abdominal discomfort. Rare adverse events (<1% of people) include: high blood level of triglycerides, liver inflammation, reversible baldness and/or ovarian hyperstimulation syndrome.<unk>  can lead to multiple ovulation, hence increasing the chance of twins (10% of births instead of ~1% in the general population) and triplets. Rates of birth defects and miscarriages do not appear to change with the use of<unk>  for fertility.<unk>  has been associated with liver abnormalities and a couple of cases of hepatotoxicity. Cancer risk Some studies have suggested that<unk>  if used for more than a year may increase the risk of ovarian cancer. This may only be the case in those who have never been and do not become pregnant. Subsequent studies have failed to support those findings.<unk>  has been shown to be associated with an increased risk of malignant melanomas and thyroid cancer. Thyroid cancer risk was not associated with the number of pregnancies carried to viability.
Clomifene
Enclomifene
Esthiomene
Intonjane
Brodifacoum
Plerixafor
Lisocabtagene maraleucel
Toremifene